explore -WSS

explore

author：leisure time 2025-10-02 23:31:44 - browse：24384

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Bird flu researchers hone in on Finland’s mink farms

knowledge

WSS

How to improve immunocompromised access to mAb treatments

Dozens dead from Maui wildfires: What we know about the victims

What to know about the judge who will handle the Trump case

Dairy farmers resist CDC push for PPE against bird flu virus

Apple Watch's A

YouTube cracks down on misinformation on cancer treatment

entertainment

explore

focus

Cancer drug shortages should be causing more outrage

Biogen’s boardroom scandal saddles CEO with first crisis

Medicare proposal to cover medical devices draws a mixed reaction

After Optum profits sink, UnitedHealth makes changes

Continuity nursing helped my family in our darkest PICU moments

After gene therapy, two congenitally deaf children hear for the first time

Dobbs anniversary: the lost opportunity of abortion as health care

Judge sides with young activists in first

Peter Hotez and the public health issue of online harassment

Senators push IRS to launch nonprofit hospital probe

focus

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Brain worms: The science behind RFK Jr.'s parasitic infection

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Patients, digital health players weigh in on FTC's data privacy plan

Study: AI not yet building 'n

Megan Rapinoe shares emotional post following US Women's World Cup exit

focus

knowledge

hotspot

explore